Cover Image

全球T細胞淋巴瘤市場 & 臨床實驗平台考察

Global T-Cell Lymphoma Market & Clinical Pipeline Insight

出版商 KuicK Research 商品編碼 353499
出版日期 內容資訊 英文 168 Pages
商品交期: 最快1-2個工作天內
Back to Top
全球T細胞淋巴瘤市場 & 臨床實驗平台考察 Global T-Cell Lymphoma Market & Clinical Pipeline Insight
出版日期: 2016年03月03日 內容資訊: 英文 168 Pages


第1章 T細胞淋巴瘤市場分析

第2章 T細胞淋巴瘤治療的機制

第3章 T細胞淋巴瘤治療藥市場概要

  • 目前市場情況
  • T細胞淋巴瘤的臨床開發平台概要

第4章 T細胞淋巴瘤治療藥市場動態

  • 可喜的市場參數
  • 商業化的課題

第5章 T細胞淋巴瘤治療藥市場未來展望

第6章 T細胞淋巴瘤治療藥的臨床實驗平台:各企業 & 相位

  • 研究中
  • 前臨床
  • 臨床
  • 第一階段
  • 第一/二階段
  • 第二階段
  • 第二/三階段
  • 第三階段

第7章 已上市T細胞淋巴瘤治療藥臨床考察

  • Belinostat (Beleodaq)
  • Denileukin Diftitox (ONTAK)
  • Mogamulizumab (Poteligeo)
  • Brentuximab Vedotin (Adcetris)
  • Pralatrexate (Difolta/Folotyn)
  • Interferon gamma 1a Biosimilar (Imunomax-γ)
  • Nelarabine (Arranon/ Atriance)
  • Vorinostat (Zolinza)
  • Romidepsin (Istodax)
  • Bexarotene Topical (Targretin Gel)
  • Bexarotene Oral (Targretin Oral)
  • Chlormethine (Ledaga/Valchlor
  • Methoxsalen Solution (UVADEX)
  • Mogamulizumab Companion Diagnostics (Poteligeo Test FCM/IHC)
  • Interferon alpha-2a (Roferon-A)

第8章 臨床實驗平台的T細胞淋巴瘤治療藥的開發中止、沒有報告

  • 中止
  • 沒有報告

第9章 競爭情形

  • Actelion Pharmaceuticals
  • Allos Therapeutics
  • Astellas Pharma
  • BioCryst Pharmaceuticals
  • Bristol-Myers Squibb
  • Chipscreen Biosciences
  • Celgene Corporation
  • Eisai
  • Genmab
  • Galderma
  • Inovio Pharmaceuticals
  • Johnson & Johnson Pharmaceutical Research & Development
  • Karyopharm Therapeutics
  • Kyowa Hakko Kirin
  • 日本化藥
  • Novartis
  • Neumedicines
  • Onyx Pharmaceuticals
  • Roche
  • Seattle Genetics
  • 鹽野義製藥
  • Soligenix
  • TetraLogic Pharmaceuticals
  • ZIOPHARM Oncology



Immune system consists of various cells that impart resistance to body against foreign entities. They also prevent the development of aberrant cells in the body to maintain its normal functioning. However, it has been noted that these cells are also liable for deterioration leading to diseases development. For instance, T-cell lymphoma is cancer causing unrestricted growth of T-cells leading to impaired immune system. Investigators have identified different T-cell malignancies that cause high morbidity and mortality. As a result, several cancer therapeutics have been developed in past years to prevent T-cell lymphoma proliferation and progression.

T-cell lymphoma is divided into several disease segments based on their pathophysiology that causes difficulty in identification and treatment. Most of the therapeutics have been developed for the Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-cell Lymphoma (CTCL) which affects blood and skin, respectively. Other subcategories of T-cell lymphoma are largely untouched due to which large unmet necessities could be observed. For instance, Adult T-cell lymphoma is found in 2%-5% patients suffering from Human T-Lymphotropic Viruses, type I (HTLV-1) infection. Generally chemotherapeutics approaches are used which have modest safety and efficacy profiles. As a result, appropriate therapeutics is not available leading to high unmet medical necessities giving emphasis on development of innovative modalities for T-cell lymphoma treatment.

With time, new modalities are expected to be developed as underlying principles behind T-cell lymphoma would be deciphered. For instance, investigators developed extracorporeal photopheresis as an advanced method that could improve survival in patients. Low toxicity and activation of treatment on demand are among one of the most sought features. This procedure could also be used with other therapeutics to achieve better pharmacological effects. Despite these benefits, its utility is limited because of special procedure requiring patients to stay in hospital for T-cell lymphoma treatment. This scenario indicates that more research and development is required for new and improved T-cell lymphoma therapeutics. Some of the progress has been made by developing immunotoxin, HDAC inhibitors, monoclonal antibodies and other investigational therapeutics.

Technological advancements are expected to help the investigators to develop better therapeutics and increase the discovery rates. Increased investments in research and development are expected to help in development of better therapeutic with superior pharmacological and commercialization potential. They are expected to offer severe competition to existing therapeutics due to which more revenues are expected to be generated. Lots of opportunity are available as myriad of candidates with different biological properties are under T-cell lymphoma clinical trials. Cancer market is expected to witness introduction of several innovative products which will help the pharmaceutical companies to generate significant revenues. These products are at different stages of clinical trials due to which they would take some time before entering in global market. In this way, future T-cell lymphoma therapeutics looks optimistic due to their superior pharmacological profiles.

“Global T-Cell Lymphoma Market & Clinical Pipeline Insight” Report Highlight:

  • Mechanism of T-Cell Lymphoma Therapeutics
  • T-Cell Lymphoma Drug Market Overview
  • T-Cell Lymphoma Drug Clinical Pipeline By Company & Phase
  • T-Cell Lymphoma Drug Clinical Pipeline By Peripheral & Cutaneous T-cell Lymphoma
  • T-Cell Lymphoma Drug Clinical Pipeline: 24 Drugs
  • Orphan Designated T-Cell Lymphoma Drugs: 22 Drugs
  • Marketed T-Cell Lymphoma Drug Clinical Insight
  • Marketed T-Cell Lymphoma Drugs: 15 Drugs
  • T-Cell Lymphoma Drug Market Future Prospects

Table of Contents

1. T-Cell Lymphoma Market Analysis

2. Mechanism of T-Cell Lymphoma Therapeutics

3. T-Cell Lymphoma Drug Market Overview

  • 3.1. Current Market Scenario
  • 3.2. T Cell Lymphoma Clinical Pipeline Overview

4. T-Cell Lymphoma Drug Market Dynamics

  • 4.1. Favorable Market Parameters
  • 4.2. Commercialization Challenges

5. T-Cell Lymphoma Drug Market Future Prospects

6. T Cell Lymphoma Drug Clinical Pipeline By Company & Phase

  • 6.1. Research
  • 6.2. Preclinical
  • 6.3. Clinical
  • 6.4. Phase-I
  • 6.5. Phase-I/II
  • 6.6. Phase-II
  • 6.7. Phase-II/III
  • 6.8. Phase-III

7. Marketed T Cell Lymphoma Drug Clinical Insight

  • 7.1. Belinostat (Beleodaq)
  • 7.2. Denileukin Diftitox (ONTAK)
  • 7.3. Mogamulizumab (Poteligeo)
  • 7.4. Brentuximab Vedotin (Adcetris)
  • 7.5. Pralatrexate (Difolta/Folotyn)
  • 7.6. Interferon gamma 1a Biosimilar (Imunomax-γ)
  • 7.7. Nelarabine (Arranon/ Atriance)
  • 7.8. Vorinostat (Zolinza)
  • 7.9. Romidepsin (Istodax)
  • 7.10. Bexarotene Topical (Targretin Gel)
  • 7.11. Bexarotene Oral (Targretin Oral)
  • 7.12. Chlormethine (Ledaga/Valchlor
  • 7.13. Methoxsalen Solution (UVADEX)
  • 7.14. Mogamulizumab Companion Diagnostics (Poteligeo Test FCM/IHC)
  • 7.15. Interferon alpha-2a (Roferon-A)

8. Discontinued & No Development Reported in T-Cell Lymphoma Drug in Clinical Pipeline

  • 8.1. Discontinued
  • 8.2. No Development Reported

9. Competitive Landscape

  • 9.1. Actelion Pharmaceuticals
  • 9.2. Allos Therapeutics
  • 9.3. Astellas Pharma
  • 9.4. BioCryst Pharmaceuticals
  • 9.5. Bristol-Myers Squibb
  • 9.6. Chipscreen Biosciences
  • 9.7. Celgene Corporation
  • 9.8. Eisai
  • 9.9. Genmab
  • 9.10. Galderma
  • 9.11. Inovio Pharmaceuticals
  • 9.12. Johnson & Johnson Pharmaceutical Research & Development
  • 9.13. Karyopharm Therapeutics
  • 9.14. Kyowa Hakko Kirin
  • 9.15. Nippon Kayaku
  • 9.16. Novartis
  • 9.17. Neumedicines
  • 9.18. Onyx Pharmaceuticals
  • 9.19. Roche
  • 9.20. Seattle Genetics
  • 9.21. Shionogi
  • 9.22. Soligenix
  • 9.23. TetraLogic Pharmaceuticals
  • 9.24. ZIOPHARM Oncology

List of Figures

  • Figure 1-1: Main Types of Blood Cancer
  • Figure 1-2: Types of White Blood Cells (WBC)
  • Figure 1-3: Types of Lymphoma
  • Figure 1-4: Major Type of T-Cell Lymphoma
  • Figure 1-5: Type of Anaplastic Large Cell Lymphoma
  • Figure 1-6: Type of Uncommon T-Cell Lymphomas
  • Figure 2-1: Extracorporeal Photopheresis (ECPP)
  • Figure 2-2: Mechanism of Bexarotene
  • Figure 2-3: Mechanism of Pralatrexate
  • Figure 2-4: Mechanism of Vorinostat
  • Figure 2-5: Mechanism of Denileukin Diftitox
  • Figure 2-6: Mechanism of Romidepsin
  • Figure 2-7: Mechanism of Alemtuzumab
  • Figure 3-1: T-Cell Lymphoma Pipeline by Phase(%), 2016
  • Figure 3-2: T-Cell Lymphoma Pipeline by Phase(Numbers), 2016
  • Figure 3-3: T-Cell Lymphoma Pipeline by Phase (%), 2016
  • Figure 3-4: T-Cell Lymphoma Pipeline by Phase (Numbers), 2016
  • Figure 4-1: T-Cell Lymphoma Drug Market Favorable Parameters
  • Figure 4-1: T-Cell Lymphoma Drug Market Commercialization Challenges

List of Tables

  • Table 1-1: Staging of T-Cell Lymphoma
Back to Top